公开(公告)号：US20250129166A1

公开(公告)日：2025-04-24

申请号：US18939765

申请日：2024-11-07

Applicant: Five Prime Therapeutics, Inc. ,  Bristol-Myers Squibb Company

Inventor： Robert J. Johnston ,  Arvind Rajpal ,  Paul O. Sheppard ,  Luis Borges ,  Andrew Rankin ,  Keith Sadoon Bahjat ,  Alan J. Korman ,  Xiaodi Deng ,  Lin Hui Su ,  Ginger Rakestraw ,  Jason R. Pinckney ,  David A. Critton ,  Guodong Chen ,  Richard Y. Huang ,  Ekaterina G. Deyanova

IPC: C07K16/28 ,  A61K38/16 ,  C07K16/46

Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.

公开(公告)号：US11623965B2

公开(公告)日：2023-04-11

申请号：US16103654

申请日：2018-08-14

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Stanley R. Krystek, Jr. ,  Yong Zhang ,  Gregory D. Vite ,  Arvind Rajpal ,  Chetana Rao-Naik ,  Paul E. Morin ,  Mohan Srinivasan ,  Zheng Lin ,  Virginie Lafont ,  Alla Pritsker

IPC: C07K16/46 ,  A61K39/395 ,  A61K47/60 ,  A61K47/65 ,  C07K16/28 ,  A61P29/00 ,  A61P35/00

Abstract: A prodrugged antibody has a blocking moiety attached to a Cys on its heavy or light chain via a linker having a cleavable moiety. The blocking moiety inhibits binding of the antibody to its antigen. Cleavage of the cleavable moiety releases the blocking moiety and restores ability of the antibody to bind to its antigen.

公开(公告)号：US11306150B2

公开(公告)日：2022-04-19

申请号：US16476814

申请日：2018-01-10

Applicant: Bristol-Myers Squibb Company ,  Five Prime Therapeutics, Inc.

Inventor： Robert J. Johnston ,  Andrew Rankin ,  Arathi Krishnakumar ,  Paul O. Sheppard ,  Arvind Rajpal

IPC: C07K16/28 ,  A61K45/06

Abstract: Methods of identifying and using PSGL-1 antagonists are provided. Such methods include, but are not limited to, methods of treating cancer. PSGL-1 antagonists include, but are not limited to, antibodies that bind PSGL-1 and antibodies that bind VISTA, wherein the antibodies inhibit PSGL-1 binding to VISTA, e.g., at acidic pH (e.g., pH 6.0), as well as PSGL-1 and VISTA extracellular domain polypeptides.

公开(公告)号：US20190330364A1

公开(公告)日：2019-10-31

申请号：US16476814

申请日：2018-01-10

Applicant: Bristol-Myers Squibb Company ,  Five Prime Therapeutics, Inc.

Inventor： Robert J. Johnston ,  Andrew Rankin ,  Arathi Krishnakumar ,  Paul O. Sheppard ,  Arvind Rajpal

IPC: C07K16/28

Abstract: Methods of identifying and using PSGL-1 antagonists are provided. Such methods include, but are not limited to, methods of treating cancer. PSGL-1 antagonists include, but are not limited to, antibodies that bind PSGL-1 and antibodies that bind VISTA, wherein the antibodies inhibit PSGL-1 binding to VISTA, e.g., at acidic pH (e.g., pH 6.0), as well as PSGL-1 and VISTA extracellular domain polypeptides.

公开(公告)号：US09840562B2

公开(公告)日：2017-12-12

申请号：US14692948

申请日：2015-04-22

Applicant: Pfizer Inc. ,  Bristol-Myers Squibb Company

Inventor： Jing Min ,  Yanli Wu ,  Rory F. Finn ,  Barrett R. Thiele ,  Wei Liao ,  Ronald P. Gladue ,  Arvind Rajpal ,  Timothy J. Paradis ,  Peter Brams ,  Brigitte Devaux ,  Yi Wu ,  Kristopher Toy ,  Heidi N. LeBlanc ,  Haichun Huang

IPC: C07K16/28 ,  A61K39/00

CPC classification number: C07K16/2878 ,  A61K2039/505 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/92

Abstract: The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.